Collegium Operating Income from 2010 to 2026
| COLL Stock | USD 39.99 1.61 3.87% |
Operating Income | First Reported 2013-12-31 | Previous Quarter 63.6 M | Current Value 59.2 M | Quarterly Volatility 25 M |
Check Collegium Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collegium Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 237.4 M, Interest Expense of 86.4 M or Selling General Administrative of 105.2 M, as well as many indicators such as Price To Sales Ratio of 1.79, Dividend Yield of 0.0721 or PTB Ratio of 5.14. Collegium financial statements analysis is a perfect complement when working with Collegium Pharmaceutical Valuation or Volatility modules.
Collegium | Operating Income | Build AI portfolio with Collegium Stock |
Historical Operating Income data for Collegium Pharmaceutical serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Collegium Pharmaceutical represents a compelling investment opportunity.
Latest Collegium Pharmaceutical's Operating Income Growth Pattern
Below is the plot of the Operating Income of Collegium Pharmaceutical over the last few years. Operating Income is the amount of profit realized from Collegium Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Collegium Pharmaceutical is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Collegium Pharmaceutical's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collegium Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Operating Income | 10 Years Trend |
|
Operating Income |
| Timeline |
Collegium Operating Income Regression Statistics
| Arithmetic Mean | 29,697,365 | |
| Geometric Mean | 41,898,538 | |
| Coefficient Of Variation | 312.18 | |
| Mean Deviation | 74,322,943 | |
| Median | (16,042,000) | |
| Standard Deviation | 92,709,114 | |
| Sample Variance | 8595T | |
| Range | 290.5M | |
| R-Value | 0.78 | |
| Mean Square Error | 3590.9T | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 14,319,188 | |
| Total Sum of Squares | 137519.7T |
Collegium Operating Income History
Other Fundumenentals of Collegium Pharmaceutical
Collegium Pharmaceutical Operating Income component correlations
Click cells to compare fundamentals
About Collegium Pharmaceutical Financial Statements
Collegium Pharmaceutical investors utilize fundamental indicators, such as Operating Income, to predict how Collegium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Operating Income | 187.1 M | 196.4 M | |
| Non Operating Income Net Other | 1.2 M | 694.8 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Collegium Pharmaceutical Correlation against competitors. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.315 | Earnings Share 1.63 | Revenue Per Share | Quarterly Revenue Growth 0.129 | Return On Assets |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.